AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02938520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) tablet
Description: It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose.
Study NCT04464668 — intervention group
Intervention type: BEHAVIORAL
Intervention: Provider surveys
Description: Remote/electronic data collection surveys will be conducted with clinic institution leaders, cancer control champions, and providers from various clinic locations to solicit feedback about implementation processes at three time points (baseline, mid-point and end of study implementation)
Study NCT03085901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precizon toric intraocular lens
Description: Phacoemulsification and implantation of Precizon toric intraocular lens
Study NCT03085901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis toric intraocular lens
Description: Phacoemulsification and implantation of Tecnis toric intraocular lens
Study NCT03386656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amchafibrin
Description: Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
Study NCT03386656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo
Study NCT01525927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Chemotherapy for three cycles prior to radiotherapy
Study NCT01525927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Chemotherapy for three cycles prior to radiotherapy
Study NCT01525927 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
Study NCT01525927 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced dose radiotherapy
Description: Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
Study NCT04640207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facial skin treatment
Description: Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
Study NCT02393573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients will take metformin for two weeks before Surgery and 2 days after the surgery
Study NCT02393573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
Study NCT02977013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-Xa assay
Description: Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
Study NCT03331666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
Study NCT03331666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evolocumab
Description: 140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
Study NCT01200615 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wording of the explenation on side-effects as part of the informed consent.
Description: Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
Study NCT04638712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microbiopsy sample
Description: before and after chemotherapy
Study NCT04638712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level
Description: before and after chemotherapy
Study NCT05108220 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Cannabidiol (CBD)- containing consumer products
Description: Oils or capsules containing CBD which could be purchased commercially within the U.S.
Study NCT00877669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of the prostate
Description: Standard transurethral resection of the prostate using electrocautery loop
Study NCT00877669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of the Prostate
Description: HoLEP using 100W Ho:YAG laser
Study NCT04287101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-operative PT and OT
Description: Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
Study NCT04287101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative PT and OT
Description: Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
Study NCT04301921 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional punkcture site and No anticoagulation
Description: Traditional punkcture site and No anticoagulation
Study NCT04301921 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional punkcture site and ACT-guided anticoagulation
Description: Traditional punkcture site and ACT-guided anticoagulation
Study NCT01722487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
Study NCT01722487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
Study NCT01450046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-Tocotrienol
Description: Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
Study NCT00670397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: IV
Study NCT02675894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cooled-wet electrode
Description: RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
Study NCT02675894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: separable clustered electrode
Description: RFA is performed using separable clustered electrode in switching monopolar mode.
Study NCT03849495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D745
Description: Reference drug
Study NCT02856685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
Study NCT01724983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Study NCT01724983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study NCT02598466 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Study NCT04981015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Three-day bladder diary
Description: A three-day bladder diary for recording voiding-flow pattern of a women
Study NCT01462058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 70µg Vitamin D3, daily, 12 weeks
Study NCT01462058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily, 12 weeks
Study NCT02938520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir - Injectable Suspension (CAB LA)
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
Study NCT02938520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine - Injectable Suspension (RPV LA)
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Study NCT04411212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte colony-stimulating factor and platelet-rich plasma group
Description: Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
Study NCT01985269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home visits
Description: The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
Study NCT04373590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.
Study NCT02750072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrapatellar Approach
Description: Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
Study NCT02750072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprapatellar Approach
Description: Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
Study NCT00487708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Study NCT03745131 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw to obtain serum to determine anti-orthopox antibody titres.
Study NCT00748150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
Description: 1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
Study NCT04992156 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib 125mg/d
Study NCT01266265 — intervention group
Intervention type: DRUG
Intervention: inhaled prostacyclin
Description: Tyvaso
Study NCT01266265 — intervention group
Intervention type: DRUG
Intervention: inhaled prostacyclin
Description: As prescribed by the physician
Study NCT01266265 — intervention group
Intervention type: DRUG
Intervention: prostacyclin
Description: As prescribed by the physician
Study NCT01266265 — intervention group
Intervention type: DRUG
Intervention: subcutaneous and intravenous prostacyclin
Description: As prescribed by physician
Study NCT01266265 — intervention group
Intervention type: DRUG
Intervention: oral ERA
Description: As prescribed by physician
Study NCT01266265 — intervention group
Intervention type: DRUG
Intervention: oral PDE5 inhibitors
Description: As prescribed by physician
Study NCT02938520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/DTG/3TC STR - Tablet
Description: It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
Study NCT04411212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
Study NCT02619318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balancing Everyday Life (BEL)
Study NCT02619318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual (generally standard occupational therapy)
Study NCT03832153 — intervention group
Intervention type: PROCEDURE
Intervention: thrombus aspiration
Description: Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
Study NCT02750904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental plus Nicotine Replacement Therapy
Description: Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study.
Study NCT02750904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control plus Nicotine Replacement Therapy
Description: Includes four in-person and four phone visits
Study NCT03569865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
Study NCT03569865 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Audiovisual Stimulation
Description: A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
Study NCT01976936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Lovastatin
Description: 80 mg daily for 3 days
Study NCT01976936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 days
Study NCT01976936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Lovastatin
Description: 640 mg daily for 3 days
Study NCT02702518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhDNase I
Description: rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
Study NCT02702518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Drug vehicle 4 times a day for 8 weeks
Study NCT03661489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of general anesthesia
Study NCT03661489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction and maintenance of general anesthesia
Study NCT00618449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromcyin
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
Study NCT00618449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
Study NCT02273557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation I - low)
Study NCT02273557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation III - medium)
Study NCT02273557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation II - high)
Study NCT02273557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER (present commercial formulation)
Study NCT04096326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection.
Study NCT04096326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection.
Study NCT02938520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG Tablet
Description: It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate.
Study NCT01084434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Bifidobacterium lactis HN019 10\^9 CFU/day 1 sachet once a day for 7 weeks
Study NCT01084434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotic
Description: Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
Study NCT01084434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: (Bifidobacterium lactis 10\^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
Study NCT01084434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
Study NCT04555304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH903 + Paclitaxel
Description: KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
Study NCT04555304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Paclitaxel
Description: Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
Study NCT03595163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
Study NCT03595163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
Study NCT02019082 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation (BTL-5000 series, United Kingdom)
Description: Direct current ES